Top Suppliers:I want be here


  • DC Chemicals Limited
  • China
  • Product Name: Gefarnate
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

51-77-4

51-77-4 structure
51-77-4 structure
  • Name: Gefarnate
  • Chemical Name: [(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
  • CAS Number: 51-77-4
  • Molecular Formula: C27H44O2
  • Molecular Weight: 400.637
  • Catalog: API Digestive system medication Gastrointestinal expectorant
  • Create Date: 2018-07-19 15:44:47
  • Modify Date: 2024-01-04 20:26:25
  • Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.

Name [(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
Synonyms Gepharnate
arsanyl
(2E)-3,7-Dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate
Gefanil
Gefarnate [INN:BAN:JAN]
(E)-Geranyl (E,E)-farnesylacetate
Gefarnyl
Osteol
EINECS 200-121-0
trans-(4,5),trans-(8,9)-Farnesylessigsaeure-geranylester
Gefarnate
(2E)-3,7-Dimethyl-2,6-octadien-1-yl (4E,8E)-5,9,13-trimethyl-4,8,12-tetradecatrienoate
(4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoic acid [(2E)-3,7-dimethylocta-2,6-dienyl] ester
DA-688
Gefarnato [INN-Spanish]
Geranyl farnesylacetate
5,9,13-Trimethyl-4,8,12-tetradecatrienoic acid 3,7-dimethyl-2,6-octadienyl ester
(4E,8E)-Farnesylacetic acid geranyl ester
Gefarnil
Gefarnatum [INN-Latin]
4,8,12-Tetradecatrienoic acid, 5,9,13-trimethyl-, (2E)-3,7-dimethyl-2,6-octadien-1-yl ester, (4E,8E)-
Description Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.
Related Catalog
In Vitro Gefarnate (0.001, 0.01, or 0.1 mg/mL) increases mucin-like glycoprotein secretion in a dose-dependent fashion, but the difference from the control is significant only at the concentration of 0.1 mg/mL. Gefarnate specifically stimulates the mucin-like glycoprotein secretion[1].
References

[1]. Nakamura M, et al. Gefarnate stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo. Exp Eye Res. 1997 Oct;65(4):569-74.

Density 0.9±0.1 g/cm3
Boiling Point 484.7±34.0 °C at 760 mmHg
Melting Point 25°C
Molecular Formula C27H44O2
Molecular Weight 400.637
Flash Point 93.3±24.0 °C
Exact Mass 400.334137
PSA 26.30000
LogP 10.53
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.489

CHEMICAL IDENTIFICATION

RTECS NUMBER :
XB8890000
CHEMICAL NAME :
4,8,12-Tetradecatrienoic acid, 5,9,13-trimethyl-, 3,7-dimethyl-2,6-octadienyl ester, (E,E,E)-
CAS REGISTRY NUMBER :
51-77-4
LAST UPDATED :
199701
DATA ITEMS CITED :
8
MOLECULAR FORMULA :
C27-H44-O2
MOLECULAR WEIGHT :
400.71
WISWESSER LINE NOTATION :
1Y1&U3Y1&U3Y1&U3VO2UY1&3UY1&1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>9 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,266,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2040 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,266,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>13500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,266,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>8 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 6,457,1963
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>4 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 6,457,1963
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2821 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 6,457,1963
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>13500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,266,1982

~75%

51-77-4 structure

51-77-4

Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798

~%

51-77-4 structure

51-77-4

Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798

~%

51-77-4 structure

51-77-4

Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798

~%

51-77-4 structure

51-77-4

Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798

~%

51-77-4 structure

51-77-4

Literature: Sato; Inoue; Sakamoto Synthesis, 1981 , vol. No.10, p. 796 - 798

~%

51-77-4 structure

51-77-4

Literature: Nigmatov, A. G.; Serebryakov, E. P.; Yanovskaya, L. A. Pharmaceutical Chemistry Journal, 1987 , vol. 21, # 7 p. 529 - 533 Khimiko-Farmatsevticheskii Zhurnal, 1987 , vol. 21, # 7 p. 854 - 858